Can statins finally provide the breakthrough in the treatment of non-alcoholic fatty liver disease?

Clin Res Hepatol Gastroenterol. 2022 Apr;46(4):101826. doi: 10.1016/j.clinre.2021.101826. Epub 2021 Oct 29.

Authors

Abia Shahid¹, Huzaifa Ahmad Cheema²

Affiliations

¹ Department of Internal Medicine, King Edward Medical University, Nila Gumbad Chowk, Neela Gumbad Lahore, Punjab 54000, Pakistan.
² Department of Internal Medicine, King Edward Medical University, Nila Gumbad Chowk, Neela Gumbad Lahore, Punjab 54000, Pakistan. Electronic address: [email protected].

PMID: 34757151
DOI: 10.1016/j.clinre.2021.101826

No abstract available

Keywords: Before-after studies; NAFLD; NASH; Review methodology; Statins.

Publication types

Letter
Comment

MeSH terms

Cardiovascular Diseases*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Hypoglycemic Agents
Non-alcoholic Fatty Liver Disease* / drug therapy

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents